CHRISTOPHER COOPER

Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease LOS ANGELES, CA NPI 1588680482

General Payments — all program years on this page

$207,362.35

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 62
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $72,604.88 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $70,302.339
Travel and Lodging $1,516.783
Food and Beverage $785.777

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
AstraZeneca UK Limited $71,892.3818
CHIESI USA, INC. $712.501

By program year

Program yearAmountRecords
2018 $14,653.173
2019 $17,209.0423
2020 $46,926.435
2021 $15,939.214
2022 $12,566.663
2023 $27,462.965
2024 $72,604.8819

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1093899377 AstraZeneca UK Limited $461.48 01/12/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1093902729 AstraZeneca UK Limited $576.80 01/12/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1093924209 AstraZeneca UK Limited $1,745.25 12/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093933462 AstraZeneca UK Limited $150.46 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1093940370 AstraZeneca UK Limited $7,066.92 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093941610 AstraZeneca UK Limited $29.10 02/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1093945143 AstraZeneca UK Limited $478.50 01/12/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1093947211 AstraZeneca UK Limited $13,779.42 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093964154 AstraZeneca UK Limited $4,070.46 02/22/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093968866 AstraZeneca UK Limited $5,686.83 11/06/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093973956 AstraZeneca UK Limited $11,545.50 02/22/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093975828 AstraZeneca UK Limited $38.96 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1093995862 AstraZeneca UK Limited $230.63 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1094002678 AstraZeneca UK Limited $12,082.50 02/22/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1094019159 AstraZeneca UK Limited $149.89 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1094028518 AstraZeneca UK Limited $13,612.95 04/16/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1094033810 AstraZeneca UK Limited $159.23 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1094037638 AstraZeneca UK Limited $27.50 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151803836 Chiesi USA, Inc. $712.50 10/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.